NEWS

Gospel for Blood Cancer Patients-Bispecific Antibody Therapy

Release time:

2020-12-10 16:08

Blood Cancer Patients Gospel-bispecific antibody therapy

Common blood cancers include various types of leukemia, multiple myeloma, and malignant lymphoma.Among them, leukemia is listed as one of the top ten malignant tumors in my country due to its high mortality rate. Therefore, how to effectively treat blood cancer and save the lives of patients with blood cancer is still the focus of research by medical workers..

In the field of immunotherapy,Bispecific antibody therapy is the use of a patient's immune systemTA way for cells to kill tumors. One end of them can bind to antigens on the surface of cancer cells, and the other end can be used.Tcell surfaceTcell receptor binding, willTcells are recruited to the vicinity of cancer cells, initiatingTCell-to-cancer cell killing, due to the bispecific antibody therapy of this different from the monoclonal antibody.Specialmechanism of action, thus making bispecific antibodies the immunotherapy community's“Newly rich”.

The following are some of the current high-profile bispecific antibodies in the research therapy, and their use in the treatment of relapse./Some new research advances have been made in refractory blood cancers:

Company

Drugs

Target

Indications

latest research progress

regenerative element

Odronextamab(REGN1979)

CD20 x CD3

RefractoryBcellular non-Hodgkin lymphoma(B-thank you)

in highly refractoryB-thank youshowed good single-agent antitumor activity in patients; in indolent and aggressiveB-thank youDurable complete remission rates were observed in all patients (CR), includingCAR-TTherapy-refractory patients; at the same time, with acceptable safety and tolerability; currently, a global2phase clinical.

regenerative element

REGN5458

BCMA x CD3

Recurrence/Refractory multiple myeloma (MM)

As2020Year6Month15Day, yes.45Patients receivedREGN5458treatment, the results showed that the overall efficiency of all dose-level groups (ORR)35.6% (the highest dose level is60%), where81.3% of respondents achieved at least a very good partial response;31.3% Patient-specific complete remission;43.8Duration of efficacy in% of responders (DoR)>4months,18.8%DOR>8months; patients with extramedullary plasmacytomaORRFor16.7%; data displayREGN5458Has an acceptable safety profile and is resistant to relapse/RefractoryMMDurable efficacy in patients.

Roche

Mosunetuzumab(M)

CD20 x CD3

diffuse largeBcell lymphoma(DLBCL)

As2020Year6Month3Day, total.36NameDLBCLPatients acceptMPlusCHOP(Cyclophosphamide+Doxorubicin+Changchun Xinyi+Prednisone) regimen treatment,27Example at least before the data cut-off date.3months of treatment, these patientsORRFor96%,CRFor85%.

IGM Biosciences

IGM-2323

CD20 x CD3

lateBCell malignant tumors

As2020Year6Month12day, in a dose escalation performed for the first time in humans1During the phase test,8The patient received4dose level of treatment, preliminary results show that at higher doses,IgM-2323improved safety and tolerability; compared with otherTcell-bound antibodies compared,IgM-2323It may have a novel mechanism of action.

Janssen Company

Teclistamab(JNJ-64007957)

BCMA x CD3

Recurrence/Refractory multiple myeloma (MM)

As2020Year7Month20day,1In the latest results of the period study,84Patients receivedTeclistamabIntravenous therapy,44Patients receivedTeclistamabSubcutaneous injection therapy, the patient'sORRFor63.8%, in which51%of patients achieved very good partial remission (VGPR），9Example patient total remission.

Pfizer

PF-06863135

BCMA x CD3

Recurrence/Refractory multiple myeloma (MM)

As2020Year4Month15day,18Patients receivedPF-06863135Subcutaneous injection therapy (dose(μg/kg)Respectively80,130,215and360), these patients had previously received-CD38treatment of monoclonal antibodies, which have4patients also received targetedBCMAof antibodies conjugated to drugs orCAR-TThe treatment of therapy. As of the data cutoff date, dose escalation was ongoing but did not reach the maximum tolerated dose (MTD). The trial data showed that in all subcutaneous dose groups, the objective response rate was33%, in the two high-dose groups (215 μg/kgand360 μg/kg)75%;2patients achieved good remission;7Patients with stable disease had the best response;PF-06863135The exposure increases proportionally with increasing dose.

Teneobium/AbbVie (AbbVie)

TNB-383B

BCMA x CD3

Relapsed/refractory multiple myeloma(MM)

At dose escalation and dose expansion1In the human clinical trial study, the group is.MMpatients, and they have received at least3treatment options, including proteasome inhibitors, immunomodulatory drugs and-CD38Monoclonal antibodies. As2020Year7Month13Day, yes.38Subjects tookTNB-383B(0.025–40mg). Research data shows:TNB-383BI'll tell you the most.40mg, no step-by-step/administered in batches; in≥ 5.4mgobserved under the initial doseORRFor52％（12/23), although each3given once a week, good relief and long-lasting (up24week) reaction.

Patients, treatment, receiving, cd3,2020, as of, mm, therapy, specific